
## F Deangelis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7101000/publications.pdf Version: 2024-02-01



F DEANCEUS

#	Article	IF	CITATIONS
1	Spatial patterns of brain lesions assessed through covariance estimations of lesional voxels in multiple Sclerosis: The SPACE-MS technique. NeuroImage: Clinical, 2022, 33, 102904.	2.7	5
2	Association of Slowly Expanding Lesions on MRI With Disability in People With Secondary Progressive Multiple Sclerosis. Neurology, 2022, 98, .	1.1	31
3	MS-SMART study: systematic sampling bias concerns – Authors' reply. Lancet Neurology, The, 2020, 19, 479-480.	10.2	0
4	NAA is a Marker of Disability in Secondary-Progressive MS: A Proton MR Spectroscopic Imaging Study. American Journal of Neuroradiology, 2020, 41, 2209-2218.	2.4	10
5	Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial. Lancet Neurology, The, 2020, 19, 214-225.	10.2	81
6	Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary progressive multiple sclerosis: the MS-SMART four-arm RCT. Efficacy and Mechanism Evaluation, 2020, 7, 1-72.	0.7	11
7	Fast bound pool fraction mapping via steadyâ€state magnetization transfer saturation using singleâ€shot EPI. Magnetic Resonance in Medicine, 2019, 82, 1025-1040.	3.0	8
8	Novel Multiple Sclerosis Drugs in the Pipeline. Clinical Pharmacology and Therapeutics, 2019, 105, 1082-1090.	4.7	3
9	Functional Connectivity Changes After Initial Treatment With Fingolimod in Multiple Sclerosis. Frontiers in Neurology, 2019, 10, 153.	2.4	13
10	New MS diagnostic criteria in practice. Practical Neurology, 2019, 19, 64-67.	1.1	4
11	Value of the central vein sign at 3T to differentiate MS from seropositive NMOSD. Neurology, 2018, 90, e1183-e1190.	1.1	71
12	Deep gray matter volume loss drives disability worsening in multiple sclerosis. Annals of Neurology, 2018, 83, 210-222.	5.3	295
13	Disease-modifying therapies for multiple sclerosis. BMJ: British Medical Journal, 2018, 363, k4674.	2.3	76
14	Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis. BMJ Open, 2018, 8, e021944.	1.9	43
15	Progression of regional grey matter atrophy in multiple sclerosis. Brain, 2018, 141, 1665-1677.	7.6	269
16	Pharmacotherapy in Secondary Progressive Multiple Sclerosis: An Overview. CNS Drugs, 2018, 32, 499-526.	5.9	18
17	Secondary Progressive Multiple Sclerosis: Definition and Measurement. CNS Drugs, 2016, 30, 517-526.	5.9	34
18	Fully automated segmentation of the cervical cord from T1-weighted MRI using PropSeg : Application to multiple sclerosis. NeuroImage: Clinical, 2016, 10, 71-77.	2.7	56